Reminder of Class Action Lawsuit Against Soleno Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy SLNO?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater risks and potential legal repercussions after the drug's commercialization, which negatively impacted the company's commercial viability.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and successful track record in this field.
- Investor Advice: Investors are advised to be cautious when selecting legal counsel, prioritizing firms with proven success in securities class actions to ensure effective representation and support throughout the legal process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.490
Low
75.00
Averages
110.50
High
125.00
Current: 39.490
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing their chance for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including risks of fluid retention in participants, leading to investor losses when the true information was revealed, highlighting major risks in the drug's commercialization.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieving the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: The firm advises investors to select qualified counsel with proven success, steering clear of firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
US Stocks Close Higher Amid Hopes for Iran Ceasefire
- Market Recovery: The S&P 500 rose by 0.44% and the Nasdaq 100 increased by 0.61%, both reaching 1.5-week highs, reflecting investor optimism regarding a potential ceasefire in Iran, which could enhance market confidence.
- Economic Data Impact: The US March ISM services index fell to 54.0, below the expected 54.9, indicating a slowdown in service sector growth, which may exert negative pressure on the stock market, prompting investors to monitor future economic trends.
- Strong Labor Market: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, while the unemployment rate unexpectedly dropped to 4.3%, indicating a robust US labor market that may provide support for the stock market.
- Oil Price Volatility: Crude oil prices rose by 1% amid escalating tensions in Iran following Trump's military threats, intensifying concerns over energy supply disruptions, which could impact the performance of related stocks.
See More
Soleno Therapeutics Surges 32.39% Following Acquisition Offer from Neurocrine Biosciences
- Acquisition Impact: Soleno Therapeutics' stock surged 32.39% to $52.26 following Neurocrine Biosciences' $53-per-share all-cash acquisition offer, reflecting strong market optimism regarding the deal.
- Volume Surge: Trading volume for Soleno reached 58 million shares, a staggering 2,148% increase over the three-month average of 2.6 million shares, indicating heightened investor interest and reaction to the acquisition news.
- Market Potential: Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome patients, has generated sales of $33 million, $66 million, and $92 million over the last three quarters since its launch in March 2025, demonstrating robust market demand.
- Strategic Long-term Value: Neurocrine's $2.9 billion acquisition of Soleno enhances its commercial drug portfolio, with VYKAT XR's intellectual property expected to last into the 2040s, providing significant long-term growth potential, especially given Neurocrine's $2.5 billion cash reserves.
See More
Soleno Therapeutics Stock Soars on Acquisition News from Neurocrine Biosciences
- Acquisition Impact: Neurocrine Biosciences' all-cash offer of $53 per share for Soleno Therapeutics led to a 32.31% surge in its stock price, closing at $52.26, indicating strong market optimism regarding the deal.
- Surge in Trading Volume: Soleno's trading volume reached 58 million shares, a staggering 2,148% increase over its three-month average of 2.6 million shares, reflecting heightened investor interest and market activity surrounding the acquisition.
- Drug Sales Performance: Soleno's flagship drug, VYKAT XR, is the only FDA-approved treatment for patients with Prader-Willi Syndrome, achieving sales of $33 million, $66 million, and $92 million over the last three quarters, showcasing its market potential.
- Long-term Strategic Value: Neurocrine's $2.9 billion acquisition proposal appears manageable given its $2.5 billion cash reserves, while VYKAT XR's intellectual property extending into the 2040s provides significant long-term growth prospects for Neurocrine.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights.
- Shareholder Rights Protection: Forian Inc. (NASDAQ:FORA) is being acquired by a consortium for $2.17 per share, prompting Halper Sadeh LLC to remind shareholders to consider their legal rights and options.
- Acquisition Terms Review: Affinity Bancshares, Inc. (NASDAQ:AFBI) is selling to Fidelity BancShares (N.C.) for $23.00 per share, with terms subject to adjustment based on adjusted stockholders' equity, necessitating shareholder awareness of potential impacts on their rights.
- Merger Transaction Impact: McCormick & Company, Incorporated (NYSE:MKC) is merging with Unilever's Foods business, resulting in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
See More
Neurocrine Acquires Soleno for $2.9 Billion
- Transaction Value: Neurocrine's acquisition of Soleno for $53 per share totals $2.9 billion, adding the Vykat XR tablet to its portfolio, thereby enhancing its market position in treating Prader-Willi syndrome.
- Financing Conditions: The transaction is not subject to any financing conditions and is expected to close within 90 days, demonstrating Neurocrine's strong execution capabilities and market confidence in its acquisition strategy.
- Analyst Rating Upgrade: Oppenheimer raised Neurocrine's price target from $192 to $220 while maintaining an ‘Outperform’ rating, viewing the acquisition as a prime example of Neurocrine's industry-leading business development expertise.
- Market Sentiment: Retail sentiment around NBIX surged from ‘neutral’ to ‘extremely bullish’, while SLNO sentiment rose from ‘bullish’ to ‘extremely bullish’, indicating strong market optimism regarding the acquisition.
See More
Reminder of Class Action Lawsuit Against Soleno Therapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26 and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, or risk losing their chance for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including risks of fluid retention in participants, leading to investor losses when the true information was revealed, highlighting major risks in the drug's commercialization.
- Law Firm Credentials: Rosen Law Firm is recognized for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieving the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: The firm advises investors to select qualified counsel with proven success, steering clear of firms that merely act as intermediaries, to ensure they receive the best legal support and potential compensation in the class action.
See More
US Stocks Close Higher Amid Hopes for Iran Ceasefire
- Market Recovery: The S&P 500 rose by 0.44% and the Nasdaq 100 increased by 0.61%, both reaching 1.5-week highs, reflecting investor optimism regarding a potential ceasefire in Iran, which could enhance market confidence.
- Economic Data Impact: The US March ISM services index fell to 54.0, below the expected 54.9, indicating a slowdown in service sector growth, which may exert negative pressure on the stock market, prompting investors to monitor future economic trends.
- Strong Labor Market: March nonfarm payrolls surged by 178,000, significantly exceeding expectations of 65,000, while the unemployment rate unexpectedly dropped to 4.3%, indicating a robust US labor market that may provide support for the stock market.
- Oil Price Volatility: Crude oil prices rose by 1% amid escalating tensions in Iran following Trump's military threats, intensifying concerns over energy supply disruptions, which could impact the performance of related stocks.
See More
Soleno Therapeutics Surges 32.39% Following Acquisition Offer from Neurocrine Biosciences
- Acquisition Impact: Soleno Therapeutics' stock surged 32.39% to $52.26 following Neurocrine Biosciences' $53-per-share all-cash acquisition offer, reflecting strong market optimism regarding the deal.
- Volume Surge: Trading volume for Soleno reached 58 million shares, a staggering 2,148% increase over the three-month average of 2.6 million shares, indicating heightened investor interest and reaction to the acquisition news.
- Market Potential: Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome patients, has generated sales of $33 million, $66 million, and $92 million over the last three quarters since its launch in March 2025, demonstrating robust market demand.
- Strategic Long-term Value: Neurocrine's $2.9 billion acquisition of Soleno enhances its commercial drug portfolio, with VYKAT XR's intellectual property expected to last into the 2040s, providing significant long-term growth potential, especially given Neurocrine's $2.5 billion cash reserves.
See More
Soleno Therapeutics Stock Soars on Acquisition News from Neurocrine Biosciences
- Acquisition Impact: Neurocrine Biosciences' all-cash offer of $53 per share for Soleno Therapeutics led to a 32.31% surge in its stock price, closing at $52.26, indicating strong market optimism regarding the deal.
- Surge in Trading Volume: Soleno's trading volume reached 58 million shares, a staggering 2,148% increase over its three-month average of 2.6 million shares, reflecting heightened investor interest and market activity surrounding the acquisition.
- Drug Sales Performance: Soleno's flagship drug, VYKAT XR, is the only FDA-approved treatment for patients with Prader-Willi Syndrome, achieving sales of $33 million, $66 million, and $92 million over the last three quarters, showcasing its market potential.
- Long-term Strategic Value: Neurocrine's $2.9 billion acquisition proposal appears manageable given its $2.5 billion cash reserves, while VYKAT XR's intellectual property extending into the 2040s provides significant long-term growth prospects for Neurocrine.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share in cash, which may infringe on shareholder rights.
- Shareholder Rights Protection: Forian Inc. (NASDAQ:FORA) is being acquired by a consortium for $2.17 per share, prompting Halper Sadeh LLC to remind shareholders to consider their legal rights and options.
- Acquisition Terms Review: Affinity Bancshares, Inc. (NASDAQ:AFBI) is selling to Fidelity BancShares (N.C.) for $23.00 per share, with terms subject to adjustment based on adjusted stockholders' equity, necessitating shareholder awareness of potential impacts on their rights.
- Merger Transaction Impact: McCormick & Company, Incorporated (NYSE:MKC) is merging with Unilever's Foods business, resulting in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
See More
Neurocrine Acquires Soleno for $2.9 Billion
- Transaction Value: Neurocrine's acquisition of Soleno for $53 per share totals $2.9 billion, adding the Vykat XR tablet to its portfolio, thereby enhancing its market position in treating Prader-Willi syndrome.
- Financing Conditions: The transaction is not subject to any financing conditions and is expected to close within 90 days, demonstrating Neurocrine's strong execution capabilities and market confidence in its acquisition strategy.
- Analyst Rating Upgrade: Oppenheimer raised Neurocrine's price target from $192 to $220 while maintaining an ‘Outperform’ rating, viewing the acquisition as a prime example of Neurocrine's industry-leading business development expertise.
- Market Sentiment: Retail sentiment around NBIX surged from ‘neutral’ to ‘extremely bullish’, while SLNO sentiment rose from ‘bullish’ to ‘extremely bullish’, indicating strong market optimism regarding the acquisition.
See More
